President Trump approves a phase one trade agreement with China.

Joseph Corr

2020-01-01 13:39:00 Wed ET

President Trump approves a phase one trade agreement with China. This approval averts the introduction of new tariffs on Chinese imports. In return, China seeks to purchase $40 billion to $50 billion U.S. agribusiness exports to better balance the current Sino-American terms of trade. The Trump administration expects to phase out gradual tariff reductions for Chinese imports.

Meanwhile, the Trump administration reduces tariffs on $120 billion to $160 billion Chinese imports from 15% to 7.5%, but the separate 25% levies would remain on $250 billion Chinese imports. On the bright side, the current trade accord proves to be mutually beneficial to China and America, so the key U.S. and Chinese stock market indices surge in response to this great deal. The greenback depreciates a bit against a basket of U.S. fair-trade partners in response to the Sino-U.S. bilateral phase-one trade deal.

On the dark side, Chinese 5G technology now crystallizes as a clear challenger to the U.S. business model. A bifurcation of global supply chains has thus gone from a new niche to a mainstream consensus view. It is hence important for the Trump administration to strike a delicate balance between fair trade details and high-tech advances.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

The bank-credit-card model and fintech platforms have adapted well to the recent digitization of cashless finance.

Daphne Basel

2023-11-30 08:29:00 Thursday ET

The bank-credit-card model and fintech platforms have adapted well to the recent digitization of cashless finance.

In addition to the OECD bank-credit-card model and Chinese online payment platforms, the open-payments gateways of UPI in India and Pix in Brazil have adapt

+See More

The new Brexit deal can boost British pound appreciation and macroeconomic optimism.

Fiona Sydney

2019-11-13 11:34:00 Wednesday ET

The new Brexit deal can boost British pound appreciation and macroeconomic optimism.

The new Brexit deal can boost British pound appreciation and economic optimism. British prime minister Boris Johnson wins the parliamentary vote on his new

+See More

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions.

Dan Rochefort

2018-05-10 07:37:00 Thursday ET

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions.

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions in their recent corporate disclosures as of mid-2018. Georg

+See More

President Trump criticizes his new Fed Chair Jerome Powell for accelerating the current interest rate hike.

Joseph Corr

2018-08-21 11:40:00 Tuesday ET

President Trump criticizes his new Fed Chair Jerome Powell for accelerating the current interest rate hike.

President Trump criticizes his new Fed Chair Jerome Powell for accelerating the current interest rate hike with greenback strength. This criticism overshado

+See More

Bank failure resolution and financial risk management: Silicon Valley Bank, Signature Bank, and First Republic Bank.

Dan Rochefort

2023-05-27 11:30:00 Saturday ET

Bank failure resolution and financial risk management: Silicon Valley Bank, Signature Bank, and First Republic Bank.

Bank failure resolution and financial risk management: Silicon Valley Bank, Signature Bank, and First Republic Bank.   What are the main root cau

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More